| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
|
J Clin Oncol
|
2003
|
3.58
|
|
2
|
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
|
J Clin Oncol
|
2013
|
2.50
|
|
3
|
Retracted
Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype.
|
Am J Respir Crit Care Med
|
2012
|
2.39
|
|
4
|
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer.
|
J Thorac Oncol
|
2015
|
2.17
|
|
5
|
A distribution-free test of constant mean in linear mixed effects models.
|
Stat Med
|
2008
|
1.97
|
|
6
|
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
|
Leuk Lymphoma
|
2008
|
1.91
|
|
7
|
Nonparametric inference on median residual life function.
|
Biometrics
|
2007
|
1.90
|
|
8
|
Accuracy of ROPtool vs individual examiners in assessing retinal vascular tortuosity.
|
Arch Ophthalmol
|
2007
|
1.81
|
|
9
|
Update on late relapse of germ cell tumor: a clinical and molecular analysis.
|
J Clin Oncol
|
2003
|
1.70
|
|
10
|
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
|
Plast Reconstr Surg
|
2003
|
1.58
|
|
11
|
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
|
Blood
|
2011
|
1.55
|
|
12
|
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
|
Leuk Lymphoma
|
2012
|
1.54
|
|
13
|
Mutational hotspots in the mitochondrial genome of lung cancer.
|
Biochem Biophys Res Commun
|
2011
|
1.54
|
|
14
|
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
|
Haematologica
|
2011
|
1.48
|
|
15
|
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
|
Leuk Lymphoma
|
2011
|
1.44
|
|
16
|
A retrospective analysis of facial fracture etiologies.
|
Ann Plast Surg
|
2008
|
1.33
|
|
17
|
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
|
J Thorac Cardiovasc Surg
|
2003
|
1.28
|
|
18
|
Gradient lasso for Cox proportional hazards model.
|
Bioinformatics
|
2009
|
1.21
|
|
19
|
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
|
Lung Cancer
|
2012
|
1.21
|
|
20
|
Statistical challenges in preprocessing in microarray experiments in cancer.
|
Clin Cancer Res
|
2008
|
1.19
|
|
21
|
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
|
Cancer Invest
|
2004
|
1.10
|
|
22
|
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
|
Mol Cancer Ther
|
2010
|
1.08
|
|
23
|
Appropriate design of prospective studies.
|
J Clin Oncol
|
2012
|
1.05
|
|
24
|
Statistical considerations for analysis of microarray experiments.
|
Clin Transl Sci
|
2011
|
1.00
|
|
25
|
A permutation-based multiple testing method for time-course microarray experiments.
|
BMC Bioinformatics
|
2009
|
1.00
|
|
26
|
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.
|
Genet Epidemiol
|
2013
|
1.00
|
|
27
|
A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
|
Stat Med
|
2003
|
0.99
|
|
28
|
Rank tests for clustered survival data when dependent subunits are randomized.
|
Stat Med
|
2006
|
0.98
|
|
29
|
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study.
|
J Clin Oncol
|
2003
|
0.98
|
|
30
|
permGPU: Using graphics processing units in RNA microarray association studies.
|
BMC Bioinformatics
|
2010
|
0.96
|
|
31
|
Designing phase II studies in cancer with time-to-event endpoints.
|
Clin Trials
|
2008
|
0.95
|
|
32
|
A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer.
|
Ann Surg
|
2016
|
0.92
|
|
33
|
Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.
|
Medicine (Baltimore)
|
2016
|
0.92
|
|
34
|
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
|
Mol Cancer Ther
|
2010
|
0.89
|
|
35
|
Postoperative prognosis prediction of pancreatic cancer with seven microRNAs.
|
Pancreas
|
2015
|
0.88
|
|
36
|
Effect of dropouts on sample size estimates for test on trends across repeated measurements.
|
J Biopharm Stat
|
2005
|
0.87
|
|
37
|
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
|
Stat Med
|
2013
|
0.87
|
|
38
|
Power and sample size calculations for SNP association studies with censored time-to-event outcomes.
|
Genet Epidemiol
|
2012
|
0.86
|
|
39
|
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
|
Invest New Drugs
|
2013
|
0.86
|
|
40
|
Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline.
|
Reprod Sci
|
2007
|
0.85
|
|
41
|
Physician self-referral of lumbar spine MRI with comparative analysis of negative study rates as a marker of utilization appropriateness.
|
AJR Am J Roentgenol
|
2012
|
0.84
|
|
42
|
Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging.
|
Eur Radiol
|
2015
|
0.84
|
|
43
|
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
|
Cancer
|
2013
|
0.83
|
|
44
|
A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
|
Int J Cancer
|
2014
|
0.82
|
|
45
|
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
|
Breast Cancer Res Treat
|
2015
|
0.82
|
|
46
|
Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization.
|
Cancer Genet Cytogenet
|
2004
|
0.82
|
|
47
|
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
|
Leuk Lymphoma
|
2013
|
0.81
|
|
48
|
A SAS macro for a clustered logrank test.
|
Comput Methods Programs Biomed
|
2011
|
0.79
|
|
49
|
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
|
Leuk Lymphoma
|
2014
|
0.79
|
|
50
|
Prediction of a time-to-event trait using genome wide SNP data.
|
BMC Bioinformatics
|
2013
|
0.79
|
|
51
|
SNP selection in genome-wide association studies via penalized support vector machine with MAX test.
|
Comput Math Methods Med
|
2013
|
0.79
|
|
52
|
Multiple testing for gene sets from microarray experiments.
|
BMC Bioinformatics
|
2011
|
0.79
|
|
53
|
Journal Club: Shoulder MRI utilization: relationship of physician MRI equipment ownership to negative study frequency.
|
AJR Am J Roentgenol
|
2013
|
0.78
|
|
54
|
Sample size calculation for simulation-based multiple-testing procedures.
|
J Biopharm Stat
|
2005
|
0.78
|
|
55
|
A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer.
|
Ann Surg
|
2016
|
0.77
|
|
56
|
Bayesian analysis of paired survival data using a bivariate exponential distribution.
|
Lifetime Data Anal
|
2007
|
0.77
|
|
57
|
Genetic profiling to predict recurrence of early cervical cancer.
|
Gynecol Oncol
|
2013
|
0.77
|
|
58
|
Does the interval of screening endoscopy affect survival in gastric cancer patients?: A cross-sectional study.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
59
|
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
60
|
Reply to M.C. Chamberlain.
|
J Clin Oncol
|
2014
|
0.75
|
|
61
|
Quantification of Aortic Valve Calcifications Detected During Lung Cancer-Screening CT Helps Stratify Subjects Necessitating Echocardiography for Aortic Stenosis Diagnosis.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
62
|
Robust test method for time-course microarray experiments.
|
BMC Bioinformatics
|
2010
|
0.75
|
|
63
|
Optimal estimation for regression models on τ-year survival probability.
|
J Biopharm Stat
|
2015
|
0.75
|
|
64
|
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
|
Am J Clin Oncol
|
2005
|
0.75
|
|
65
|
Designs for randomized phase II clinical trials with two treatment arms.
|
Stat Med
|
2013
|
0.75
|
|
66
|
Application of an adjusted chi2 statistic to site-specific data in observational dental studies.
|
J Clin Periodontol
|
2002
|
0.75
|
|
67
|
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
68
|
Journal of Biopharmaceutical Statistics. From the editors.
|
J Biopharm Stat
|
2009
|
0.75
|
|
69
|
Predictive Model for Neoplastic Potential of Gallbladder Polyp.
|
J Clin Gastroenterol
|
2017
|
0.75
|
|
70
|
A copula approach for detecting prognostic genes associated with survival outcome in microarray studies.
|
Biometrics
|
2007
|
0.75
|
|
71
|
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
72
|
Screening Magnetic Resonance Imaging-Based Prediction Model for Assessing Immediate Therapeutic Response to Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids.
|
Invest Radiol
|
2016
|
0.75
|